While associated with improved responses to ICIs, their efficacy is substantially undermined by tumor spatiotemporal heterogeneity; single-biopsy response rates in heterogeneous tumors can be as low as 15%–20%, and the concordance between PD-L1 and TMB positivity is only 54.8% (30). This evidence concerns the gene CD274 and neoplasm.